← SynDRA
TALAZOPARIB
SynDRA canonical compound SYN0037852 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PARP1 |
|---|
| Mechanism of action | PARP inhibitor |
|---|
| Indication | breast cancer |
|---|
| Disease area | oncology |
|---|
All known targets
- PARP1
- PARP2
- PARP10
- PARP16
- PARP3
- PARP4
- TNKS
Mechanisms of action (all sources)
- PARP inhibitor
- PARP2 INHIBITOR
- Poly [ADP-ribose] polymerase 2 inhibitor
- PARP1 INHIBITOR
- Poly [ADP-ribose] polymerase-1 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- TNKS2
- TIPARP
- PARP9
- PARP8
- PARP11
- ABL1
- AURKA
- PARP14
- PARP12
- MAPK1
- KCNH2
- HDAC6
- GSK3B
- FGFR2
- CYP3A4
- CYP2D6
- CYP2C9
- CYP2C19
- CYP1A2
- CSNK1D
- CDK2
- BRPF1
- BRD4
- TRIM24
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-Ribose) Polymerase Inhibitor
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- TALZENNA
- Talzenna
- talazoparib tosylate
- talzenna
- BMN-673
- BMN-673ts
- LT 006673
- LT-00673
- LT-673
- MDV-3800
- PF-06944076
- TALAZOPARIB (BMN 673)
- Talazoparib tosylate
- Talazoparib (BMN 673)
- UNII-9QHX048FRV
- 9QHX048FRV
- Talazoparib [USAN:INN]
- 4pjt
- 2YQ
- BMN 673
- Talazoparib (BMN-673)
- BMN673
- Talazoparib(BMN-673)
- TALAZOPARIB [MI]
- TALAZOPARIB [INN]
- Talazoparib (USAN/INN)
- TALAZOPARIB [USAN]
- TALAZOPARIB [WHO-DD]
- GTPL8313
- SCHEMBL2299348
- CHEMBL3137320
- BMN673,BMN-673
- DTXSID001025928
- AMY27900
- EX-A1356
- BDBM50084621
- MFCD22666357
- NSC767125
Reported adverse events
- Alopecia
- Dizziness
- Dysgeusia
- Fatigue
- Headache
- Myelosuppression
- Nausea
- Vomiting
- Decreased appetite
- Alanine aminotransferase increased
- Fracture
- Aspartate aminotransferase increased
Look up TALAZOPARIB in the interactive SynDRA portal →